Eyenovia Reports First Quarter 2025 Financial Results, Provides Update on Potential Merger With Betaliq

Published on May 21, 2025
LAGUNA HILLS, Calif.—Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company developing the proprietary Optejet topical ophthalmic medication dispensing platform, has provided updates on its potential merger with Betaliq, a clinical-stage private pharmaceutical company, and the ongoing development of its novel Optejet user filled device (UFD), and reported financial results for the first quarter ended March 31, 2025. For the first quarter of 2025, Eyenovia reported a net loss of $3.5 million. This compares with a net loss of $10.9 million for the first quarter of 2024.
Continue reading on website
Other news

ARVO 2025: OCT-based marker for accommodative effort in presbyopes

May 20, 2025
Susana Marcos, PhD, outlines a presentation she gave at ARVO 2025 on a unique utilization of optical coherence tomography.

Health care leader coalition launches Alliance for Healthcare from the Eye initiative

May 21, 2025
The cross sector initiative that intends to drive a shift from reactive to proactive health care by leveraging ocular data through the means of oculomics.